

Application No.: 10/038,760

Applicants: Anthony A. Sauvé and Vern L. Schramm


Filed: January 4, 2002

Page 2

Amendments to the claims

A listing of the claims, including Claims 1-5 as amended below, is set forth below.

1. (currently amended). A compound represented by the formula:



wherein

A is an N-linked nicotinamide group, an N-linked unsubstituted pyridyl group optionally substituted with a halogen, thiol or oxygen, ~~an N-linked substituted pyridyl group~~, or an N-linked unsubstituted pyrimidyl group, ~~an O-linked unsubstituted phenyl group, an O-linked substituted phenyl group, an O-linked unsubstituted pyridyl group, an O-linked substituted pyridyl group, an O-linked unsubstituted pyrimidyl group, an S-linked unsubstituted phenyl group, an S-linked substituted phenyl group, an S-linked unsubstituted pyridyl group, an S-linked substituted pyridyl group, or an S-linked unsubstituted pyrimidyl group~~;

B is hydrogen, or a halogen, amino, or thiol group;

C is hydrogen, or a halogen, amino, or thiol group; and

Application No.: 10/038,760

Applicants: Anthony A. Sauvé and Vern L. Schramm

Filed: January 4, 2002

Page 3

D is a primary alcohol, hydrogen, or an oxygen, nitrogen, carbon, or sulfur linked to phosphate, a phosphoryl group, a pyrophosphoryl group, or adenosine monophosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted phosphodiester bridge, or to adenosine diphosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted pyrophosphodiester bridge.

2 (currently amended). The compound of claim 1, wherein A is an N-linked nicotinamide group, ~~an N-linked unsubstituted pyridyl group, an N-linked substituted pyridyl group~~ or an N-linked unsubstituted pyrimidyl group.

3 (currently amended). The compound of claim 1 2, wherein A is ~~an N-linked nicotinamide group~~, an N-linked ~~unsubstituted~~ pyridyl group optionally substituted with a halogen, thiol or oxygen ~~or an N-linked substituted pyridyl group~~.

4 (currently amended). The compound of claim 1 3, which is a nicotinamide 2'-deoxyriboside.

5 (currently amended). The compound of claim 1 3, which is β -1'-nicotinamide-2'-deoxyribose, β -D-1'-nicotinamide-2'-deoxyribofuranoside, β -1'-pyridyl-2'-deoxyribose, or 5'-phospho-1'-pyridyl-deoxyribose.

6-9 (canceled).

10 (original). The compound of claim 1, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

11 (original). The compound of claim 2, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

Application No.: 10/038,760

Applicants: Anthony A. Sauvé and Vern L. Schramm

Filed: January 4, 2002

Page 4

12-13 (canceled).

14 (original). The compound of claim 1, wherein D is a primary alcohol or hydrogen.

15 (original). The compound of claim 2, wherein D is a primary alcohol or hydrogen.

16-29 (canceled).

30 (previously presented). The compound of claim 3, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

31-32 (canceled).

33 (previously presented). The compound of claim 3, wherein D is a primary alcohol or hydrogen.

34 (previously presented). The compound of claim 10, wherein D is a primary alcohol or hydrogen.

35 (previously presented). The compound of claim 11, wherein D is a primary alcohol or hydrogen.

36 (previously presented). A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically-acceptable carrier.

Application No.: 10/038,760

Applicants: Anthony A. Sauvé and Vern L. Schramm

Filed: January 4, 2002

Page 5

37 (previously presented). A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically-acceptable carrier.

38 (previously presented). A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically-acceptable carrier.

39 (previously presented). A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically-acceptable carrier.

40 (previously presented). A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically-acceptable carrier.

41 (previously presented). A pharmaceutical composition comprising the compound of claim 10 and a pharmaceutically-acceptable carrier.

42 (previously presented). A pharmaceutical composition comprising the compound of claim 11 and a pharmaceutically-acceptable carrier.